TY - JOUR T1 - Pathological FPCIT SPECT indicates worse survival in patients with suspected dementia. JF - Journal of Nuclear Medicine JO - J Nucl Med SP - 1651 LP - 1651 VL - 59 IS - supplement 1 AU - Franziska Henninger AU - Martin Boeker AU - Sabine Hellwig AU - Philipp Meyer AU - Lars Frings Y1 - 2018/05/01 UR - http://jnm.snmjournals.org/content/59/supplement_1/1651.abstract N2 - 1651Objectives: Dopamine transporter SPECT is an established diagnostic method for Lewy body diseases, which are associated with shortened life expectancy (Brodaty et al., 2012). This study investigated whether the clinical read of FPCIT SPECT predicts the patient’s survival. Patients from our clinical registry were included if they received an FPCIT SPECT between 10/2008 and 06/2016 and if their vital status (date of death, if applicable) could be determined in 07/2017. Cox proportional hazard models adjusted for age and sex were computed in order to test whether clinical reads of FPCIT scans (normal vs. pathological) predict survival. Analyses were stratified by indication for scanning (leading symptom: parkinsonism vs dementia). Vital status could be determined in 615/664 patients. 107 patients had died within the median follow-up duration of 3.4 years [95% C.I. 3.1 to 3.7]. In patients with parkinsonism (N = 518) FPCIT SPECT reads did not significantly predict survival. In patients with dementia (N = 97) survival time was significantly shorter in patients with a pathological FPCIT SPECT (median survival: 4.6 years; HR = 3.5 [95% C.I. 1.5 to 7.9]; p < 0.01) compared to those with a normal FPCIT SPECT (median survival not reached). A pathological FPCIT SPECT does not indicate worse survival in patients with parkinsonism. By contrast, in patients with dementia a pathological FPCIT scan is associated with a 3.5-fold increased risk to die within the next 3.4 years. This presumably reflects the higher mortality in dementia with Lewy bodies compared to Alzheimer’s dementia. ER -